NIPPON EXPRESS HOLDINGS Completes Procedure to Make Germany’s SH HoldCo Wholly-owned Subsidiary
- Completion of Acquisition (Subsidiarization) of SH HoldCo GmbH Shares - TOKYO, Feb. 14, 2025 /PRNewswire/ -- NIPPON EXPRESS HOLDINGS, INC. is pleased to announce that the agreement concluded on September 30, 2024, for the acquisition of entire shares in SH HoldCo GmbH, the parent company of the Germany-based Simon Hegele Group, was executed with effect from February...
Harbour BioMed Announces Business Progress and Update
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 14, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the latest business progress and update. Based on a preliminary review of the Company's unaudited...
Axel Klarmeyer Joins Chamlion as CEO, Chamlion International
NANJING, China, Feb. 14, 2025 /PRNewswire/ -- Chamlion, a pioneer in integrated dental 3D printing solutions, is pleased to announce the appointment of Axel Klarmeyer as the CEO of Chamlion International, overseeing the company's international business operations. Axel's extensive industry experience and leadership will be pivotal in advancing Chamlion's strategic growth and expanding its footprint globally. Axel Klarmeyer...
Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases
HONG KONG, Feb. 14, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody targeting IL-4Rα and ST2. AK139 is under investigation for a number of indications, including respiratory and skin...
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
Hanmi Pharmaceutical Global Business Headquarters Accelerates Expansion into Canadian and US Markets, Strengthening Collaboration with Distribution Partner McKesson Introducing 'Countmate': A Customized Solution for Canadian and American Pharmacists Seeking Advanced Vial Preparation Technology SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ -- Hanmi Pharmaceutical's Global Business Headquarters Overseas Sales Team...
See the Future with Luck: VISTA Eye Specialist Promotes Eye Health with CNY Eye Carnival Nationwide
PETALING JAYA, Malaysia, Feb. 14, 2025 /PRNewswire/ -- As people live longer, ensuring a purposeful and fulfilling life becomes even more important. Life expectancy in Malaysia has steadily increased to 76.26 years (), highlighting the growing need for proactive healthcare. Clear vision is crucial for maintaining independence, quality of life, and achieving personal aspirations. In response, VISTA Eye Specialist (VISTA)...
Bellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc.
SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. ("BLAC") announced today the approval of each of the proposals presented at the special meeting of its stockholders (the "Special Meeting") held today, including the proposal for the business combination with OSR Holdings Co., Ltd. (the "Transaction"). BLAC...
Regal Hotels Leverages Network to Support Hong Kong’s Healthcare Professionals with an Exclusive Long-stay Accommodation Programme
HONG KONG, Feb. 13, 2025 /PRNewswire/ -- Regal Hotels International is leveraging its extensive hotel network to launch the exclusive "Long-stay Accommodation Programme" for Hospital Authority (HA) staff. In response to the increasing demand for public healthcare services, the HA has been proactively recruiting both locally and non-locally trained healthcare professionals. Recognising...
enreap Earns 2025 Great Place To Work Certification™
PUNE, India, Feb. 13, 2025 /PRNewswire/ -- enreap is proud to be Certified™ by Great Place To Work® for the third year in a row. The prestigious award is based entirely on what current employees say about their experience working at enreap. enreap Earns 2025 Great Place To Work Certification™ Great Place To Work® is the global...
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the dosing of their first patient in the Phase Ib clinical trial of AC-101. AC-101 is a novel RIPK2 inhibitor being developed for the...
